| Q57161235 | A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research |
| Q47814036 | Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine |
| Q45391472 | Acute effects of a low-dose atropine/scopolamine mixture as a food contaminant in human volunteers |
| Q36245419 | Analysis of rapid heart rate variability in the assessment of anticholinergic drug effects in humans |
| Q38979261 | Central Aspects of Nausea and Vomiting in GI Disorders |
| Q42524569 | Cholinergic modulation of experience-dependent plasticity in human auditory cortex |
| Q34309099 | Combination therapy for postoperative nausea and vomiting - a more effective prophylaxis? |
| Q36055217 | Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. |
| Q48216446 | Cross-coupling vestibular stimulation: motion sickness and the vestibulo-sympathetic reflex. |
| Q33151694 | Electrodermal activity in patients with neurally mediated syncope |
| Q48270343 | Gastric myoelectrical and neurohormonal changes associated with nausea during tilt-induced syncope |
| Q42733296 | In vivo assessment of antiemetic drugs and mechanism of lycorine-induced nausea and emesis. |
| Q92946309 | Metabolites of Vinca Alkaloid Vinblastine: Tubulin Binding and Activation of Nausea-Associated Receptors |
| Q42592784 | Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz |
| Q38603260 | Motion Sickness: Current Knowledge and Recent Advance |
| Q37226585 | Motion sickness, nausea and thermoregulation: The "toxic" hypothesis |
| Q39017670 | Muscarinic Acetylcholine Receptors and M-Currents Underlie Efferent-Mediated Slow Excitation in Calyx-Bearing Vestibular Afferents |
| Q74404004 | Nausea and Vomiting |
| Q80823415 | Nausea and vomiting |
| Q26771877 | Nausea: a review of pathophysiology and therapeutics |
| Q37332618 | Opportunities for the replacement of animals in the study of nausea and vomiting |
| Q37559641 | Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting |
| Q51891555 | Performance and autonomic responses during motion sickness. |
| Q31805904 | Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers |
| Q35566262 | Pharmacology of Antiemetics |
| Q61796454 | Phencynonate S-isomer as a eutomer is a novel central anticholinergic drug for anti-motion sickness |
| Q28138034 | Physiological basis and pharmacology of motion sickness: an update |
| Q28377156 | Preclinical testing of N-[(11)c]-methyl-piperidin-4-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate, a novel radioligand for detection of cerebral muscarinic receptors using PET |
| Q33871354 | Prevention and treatment of postoperative nausea and vomiting |
| Q52079993 | Prokinetic effects of erythromycin after antimotion sickness drugs. |
| Q27308009 | Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors |
| Q47153756 | Scientific Opinion on Tropane alkaloids in food and feed |
| Q79190633 | Space motion sickness |
| Q88011605 | The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function |
| Q34529525 | Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications |
| Q37354119 | Treatment of nausea and vomiting in terminally ill cancer patients. |